Phase 1 N=6 A Study in Healthy Men to Test How BI 730357 is Processed by the Body
Healthy
Primary: Mass Balance Recovery of Total [14C]-Radioactivity in Urine (Feurine, 0-tz) — 34.3 Percentage of administered dose (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers
Healthy Subjects
Primary: Determine the Dose-Response of TSC on tcpO2 Following a Single Administration of TSC in Subjects Breathing O2. — 175.3; 153.1; 178.0; 179.9 mmHg
Phase 1 N=2 Blood-Stage Plasmodium Vivax Cell Bank
Malaria
Primary: P. Vivax Blood Collection — 2 Participants
Phase 1 N=6 Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
Severe Hemophilia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 1; 0; 0 Participants
Phase 1 N=102 Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
Pneumococcal Infection
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 9.8; 9.8; 54.9; 66.7 Percentage of Participants
Phase 1 N=24 A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. — 1; 0; 0 participants
Phase 1 N=12 Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
Human Immunodeficiency Virus (HIV) Infection
Primary: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma — 5.81; 7.74 Hours*μmol/Liter
Phase 1 N=8 Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Metastatic Castration Resistant Prostate Cancer
Primary: Evaluate the PK of Rucaparib in Combination With Other Anticancer Agents for mCRPC. — 1345; 233; 1558; 311 ng/ml
Phase 1 N=3 Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
Extensive Stage Lung Small Cell Carcinoma · Malignant Solid Neoplasm · Metastatic Malignant Neoplasm in the Brain
Primary: Number of Participants With Dose Limiting Toxicities — 1; 2 Participants
Phase 1 N=6 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
Human Immunodeficiency Virus
Primary: Grade 3 and Serious Adverse Events — 0 Participants
Phase 1 N=13 Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
Cocaine Dependence
Primary: Brain Glutamate Concentration in the Anterior Cingulate Cortex (ACC) in Subjects With Cocaine Use Disorder (CUD) Treated With Escalating Doses of Clavulanate (CLAV)…
Phase 1 N=25 Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids
Normal Physiology
Primary: Number of Participants Sampled for RNA-seq Differential Expression Analysis (Biological Replicates) — 5; 20 Participants
Phase 1 N=122 Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old
Influenza Vaccine
Primary: Treatment Emergent AEs During 7 Days After Experimental Treatment — 1; 0; 12; 3 Participants
Phase 1 N=61 Nicotinic Agonist Effects on BMI and Neuronal Response
Obesity
Primary: Neuronal Response to Visual Food Cues — .035; .045; .029; .019 % BOLD signal — p=0.647
Phase 1 N=40 Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
Pruritus · Cholestasis · Kidney Failure
Primary: Incidence of Adverse Events — 5; 5; 5; 3 participants